Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on January 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Pfizer stock on December 19th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.
Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):
- Sold $1,001 – $15,000 in shares of Xiaomi (OTCMKTS:XIACF) on 12/30/2025.
- Sold $1,001 – $15,000 in shares of Schneider Electric S.E. (OTCMKTS:SBGSF) on 12/30/2025.
- Sold $1,001 – $15,000 in shares of Hermès International Société en commandite par actions (OTCMKTS:HESAF) on 12/30/2025.
- Purchased $50,001 – $100,000 in shares of Campbell’s (NASDAQ:CPB) on 12/30/2025.
- Sold $1,001 – $15,000 in shares of Tencent (OTC:TCTZF) on 12/30/2025.
- Sold $1,001 – $15,000 in shares of Mitsubishi Heavy Industries (OTCMKTS:MHVYF) on 12/26/2025.
- Sold $1,001 – $15,000 in shares of Bloom Energy (NYSE:BE) on 12/24/2025.
- Sold $1,001 – $15,000 in shares of Arista Networks (NYSE:ANET) on 12/24/2025.
- Sold $1,001 – $15,000 in shares of Coinbase Global (NASDAQ:COIN) on 12/24/2025.
- Sold $1,001 – $15,000 in shares of Chevron (NYSE:CVX) on 12/24/2025.
Pfizer Stock Performance
Shares of PFE traded up $0.41 during mid-day trading on Wednesday, hitting $25.56. The stock had a trading volume of 53,710,295 shares, compared to its average volume of 46,639,645. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.69. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. The business has a fifty day moving average price of $25.29 and a 200-day moving average price of $24.97. The firm has a market cap of $145.32 billion, a P/E ratio of 14.86 and a beta of 0.47.
Pfizer Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.7%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is currently 100.00%.
Pfizer News Summary
Here are the key news stories impacting Pfizer this week:
- Positive Sentiment: Pfizer reported completion of a key China Phase 3 trial for its migraine drug rimegepant, which de-risks global regulatory and commercial rollout in a large market and supports future revenue growth. Pfizer Completes Key China Phase 3 Trial for Migraine Drug Rimegepant
- Positive Sentiment: Pfizer launched a new bioequivalence study for a CGRP migraine asset (early-stage formulation work), signaling continued investment in migraine portfolio expansion and potential lower-cost or differentiated formulations. Pfizer Advances CGRP Migraine Asset With New Bioequivalence Study
- Positive Sentiment: CEO Albert Bourla said Pfizer is pushing for an FDA priority review voucher and is positioning for a large consumer market for obesity drugs (compared to Viagra-era demand), underlining management’s focus on faster regulatory paths and new high-growth categories. These comments support upside expectations if obesity assets and regulatory wins materialize. Pfizer CEO Says Company Is Pushing for FDA Priority Review Voucher
- Positive Sentiment: Management’s obesity strategy (including the $10B Metsera buy) and public guidance about a large consumer opportunity lend optionality to Pfizer’s longer-term growth profile. Pfizer CEO plans for soaring consumer market for obesity drugs akin to Viagra
- Positive Sentiment: BMO reiterated a Buy and $30 price target, highlighting oncology and obesity pipeline upside and post-loss-of-exclusivity recovery potential—an analyst voice supporting shares. Pfizer: Underappreciated Growth Story Driven by Oncology, Obesity Pipeline, and Post-LOE Recovery Prospects
- Neutral Sentiment: Institutional owners hold ~66% of Pfizer stock, which can stabilize trading but also concentrate influence on strategy and liquidity. Pfizer Inc. (NYSE:PFE) is favoured by institutional owners who hold 66% of the company
- Neutral Sentiment: Analysts and previews expect steady oncology performance (Seagen ADCs and key brands) that could be offset by pricing and competition—results due with Q4 releases may be a near-term volatility trigger. Inside Pfizer’s Oncology Performance Ahead of Q4 Results
- Negative Sentiment: Investors remain concerned after recent weakness in the stock (market cap decline) tied to conservative 2026 guidance; commentators debate whether downside is a buying opportunity or a sign to stay cautious. Guidance-related uncertainty is pressuring the multiple. PFE Market Cap Falls More Than $7B in a Month: How to Play the Stock
- Negative Sentiment: Pfizer stopped a mid-stage lupus skin trial, trimming a potential autoimmune opportunity—a small but negative pipeline read that increases clinical risk mix. Pfizer Ends Mid-Stage Lupus Skin Trial, Trimming a Small but Promising Autoimmune Option
- Negative Sentiment: Critical commentary highlights patent cliff risk, rising debt and the challenge of sustaining buy ratings—items that keep valuation and credit metrics under investor scrutiny. Pfizer’s Patent Cliff, Rising Debt, And The Fight To Stay A Buy
Wall Street Analysts Forecast Growth
Several research firms have recently issued reports on PFE. Wolfe Research set a $24.00 price target on shares of Pfizer and gave the company an “underperform” rating in a research report on Wednesday, December 17th. Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Wednesday, December 17th. Morgan Stanley dropped their target price on Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a research report on Friday, December 12th. BMO Capital Markets reiterated an “outperform” rating on shares of Pfizer in a research report on Wednesday, December 10th. Finally, Citigroup started coverage on Pfizer in a research note on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, thirteen have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Pfizer has an average rating of “Hold” and a consensus target price of $27.88.
Check Out Our Latest Stock Report on PFE
Institutional Trading of Pfizer
Institutional investors and hedge funds have recently made changes to their positions in the stock. Meriwether Wealth & Planning LLC bought a new position in Pfizer in the fourth quarter valued at $273,000. Centennial Wealth Advisory LLC grew its holdings in Pfizer by 3.1% in the 4th quarter. Centennial Wealth Advisory LLC now owns 39,225 shares of the biopharmaceutical company’s stock worth $977,000 after acquiring an additional 1,161 shares during the last quarter. Lantz Financial LLC increased its holdings in Pfizer by 2.3% during the 4th quarter. Lantz Financial LLC now owns 46,382 shares of the biopharmaceutical company’s stock valued at $1,155,000 after purchasing an additional 1,058 shares during the period. Thompson Investment Management Inc. raised its position in Pfizer by 8.3% during the 4th quarter. Thompson Investment Management Inc. now owns 463,455 shares of the biopharmaceutical company’s stock valued at $11,540,000 after purchasing an additional 35,325 shares during the last quarter. Finally, Enterprise Financial Services Corp lifted its holdings in Pfizer by 7.9% in the 4th quarter. Enterprise Financial Services Corp now owns 25,273 shares of the biopharmaceutical company’s stock worth $629,000 after buying an additional 1,842 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.
About Representative Cisneros
Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.
Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.
Pfizer Company Profile
Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.
Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.
Further Reading
- Five stocks we like better than Pfizer
- Zacks Puts $25.50 target on BSEM!
- Punch these codes into your ordinary brokerage account
- Do not delete, read immediately
- How a Family Trust May Be Able To Help Preserve Your Wealth
- This AI Opportunity Was Built to Evolve With Demand
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
